Sentry Investment Management LLC trimmed its holdings in shares of Iqvia Holdings Inc (NYSE:IQV) by 8.2% during the first quarter, HoldingsChannel.com reports. The fund owned 8,786 shares of the medical research company’s stock after selling 781 shares during the quarter. Sentry Investment Management LLC’s holdings in Iqvia were worth $1,264,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. C J Advisory Inc acquired a new stake in Iqvia during the first quarter worth about $27,000. Baystate Wealth Management LLC acquired a new stake in Iqvia during the first quarter worth about $27,000. Parkside Financial Bank & Trust grew its stake in Iqvia by 140.2% during the first quarter. Parkside Financial Bank & Trust now owns 209 shares of the medical research company’s stock worth $30,000 after buying an additional 122 shares in the last quarter. Berman Capital Advisors LLC acquired a new stake in Iqvia during the fourth quarter worth about $46,000. Finally, ERTS Wealth Advisors LLC acquired a new stake in Iqvia during the fourth quarter worth about $46,000. 91.47% of the stock is currently owned by institutional investors and hedge funds.
IQV opened at $134.57 on Wednesday. Iqvia Holdings Inc has a 1-year low of $97.64 and a 1-year high of $146.10. The company has a debt-to-equity ratio of 1.69, a quick ratio of 1.14 and a current ratio of 1.14. The company has a market capitalization of $26.37 billion, a PE ratio of 26.28, a P/E/G ratio of 1.62 and a beta of 0.80.
In other news, Director Group Holdings (Sbs) Advis Tpg sold 4,044,480 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $140.80, for a total value of $569,462,784.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Michael J. Evanisko sold 1,193 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $144.95, for a total transaction of $172,925.35. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 4,187,753 shares of company stock worth $589,529,674. 6.00% of the stock is currently owned by corporate insiders.
A number of brokerages have issued reports on IQV. Zacks Investment Research upgraded shares of Iqvia from a “sell” rating to a “hold” rating in a research note on Friday, May 3rd. TheStreet downgraded shares of Iqvia from a “b” rating to a “c+” rating in a research note on Wednesday, May 1st. Wolfe Research began coverage on shares of Iqvia in a research note on Tuesday, April 2nd. They set a “market perform” rating on the stock. Argus increased their price objective on shares of Iqvia from $140.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, February 25th. They noted that the move was a valuation call. Finally, Piper Jaffray Companies increased their price objective on shares of Iqvia to $148.00 and gave the stock a “neutral” rating in a research note on Friday, February 15th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $146.88.
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also: SEC Filing
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.